Piper Sandler Adjusts Price Target on Inspire Medical Systems
Piper Sandler maintained its Neutral rating on Inspire Medical Systems while increasing its price target from $60 to $70.
Stocks · News reference
8-K filing — Inspire Medical Systems, Inc. (INSP)
Filed: 2026-11-02 AccNo: 0001609550-26-000051 Size: 6 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Inspire Medical Systems to Present at Stifel 2026 Healthcare Conference
Inspire Medical Systems announced that its management team is scheduled to present at the Stifel 2026 Healthcare Conference on November 10, 2026.
Baird Maintains Neutral Rating on Inspire Medical Systems and Raises Price Target
Baird maintained its Neutral rating on Inspire Medical Systems while increasing its price target from $73 to $77.
Inspire Medical Systems Reports Third Quarter 2026 Financial Results
Inspire Medical Systems reported third quarter 2026 financial results, including revenue of $206.7 million and adjusted diluted EPS of $0.14, while announcing new CPT code approvals for its Inspire V system.
Joe DiMaggio Children's Hospital Performs First Pediatric Inspire Implantation for Down Syndrome Patient
Joe DiMaggio Children's Hospital has successfully performed its first implantation of an Inspire hypoglossal nerve stimulation device in a teenage patient with Down syndrome and obstructive sleep apnea.
Here's How Tempus AI Demonstrates Improving Operating Leverage
Tempus AI demonstrated improving operating leverage in Q2 2026 with 22% revenue growth to $382.5M and adjusted EBITDA reaching $8M (a $13.6M improvement). The company completed a $460M convertible notes offering expected to reduce annual interest expenses by over $30M. Tempus raised its 2026 revenue guidance to $1.595-$1.605B while maintaining adjusted EBITDA guidance of $65M, supporting its goal of achieving positive free cash flow by year-end 2026.